When was Design Therapeutics founded?

Design Therapeutics was founded in 2006 and raised its 1st funding round 13 years after it was founded.

Where is Design Therapeutics located?

Design Therapeutics is headquartered in Carlsbad, United States. It is registered at Carlsbad (United States).

How many employees does Design Therapeutics have?

As of Jul 31, 2026, the latest employee count at Design Therapeutics is 67.

Is Design Therapeutics a funded company?

Design Therapeutics is a funded company, having raised a total of $171M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jan 07, 2019.

When was the latest funding round of Design Therapeutics?

Design Therapeutics' latest funding was a $***** Series B round on Jan 27, 2021, with participation from 8 investors.

What is the annual revenue of Design Therapeutics?

Annual revenue of Design Therapeutics is less than $1M as on Dec 31, 2020

Where does Design Therapeutics rank among its competitors?

Design Therapeutics ranks 35th amongst 278 active competitors, of which 78 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Design Therapeutics?

Design Therapeutics' top competitors include BridgeBio, Alnylam and Alexion. Among them, BridgeBio secured the most recent funding round in April, 2024.

Design Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Design Therapeutics is a public company based in Carlsbad (United States), founded in 2006 by Aseem Ansari. It operates as a Develops disease-modifying therapies for degenerative disorders. Design Therapeutics has raised $171M in funding from investors like SR One, WestRiver Group and Logos. The company has 278 active competitors, including 78 funded and 96 that have exited. Its top competitors include companies like BridgeBio, Alnylam and Alexion.

Company Details

Website: www.designtx.com/
Email ID: *****@designtx.com
Registered Address: Carlsbad (United States)

Key Metrics

Founded Year

2006

Location

Carlsbad, United States

Stage

Public

Total Funding

$171M in 5 rounds

Latest Funding Round

Series B, Jan 27, 2021, $*****

Investors

SR One & 12 more

Ranked

35^th among 278 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2020

Employee Count

67 as on Jul 31, 2026

Similar Companies

BridgeBio & 312 more

Exit Details

Public

View Design Therapeutics' full profile

Design Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
DESIGN THERAPEUTICS, INC. CIN: 1807120 , United States, Active	Dec 17, 2017	$0 - $1M (As on Dec 31, 2020)	58 (As on Dec 31, 2022)	-
Design Therapeutics, Inc. CIN: 82-3929248 , United States, Active	Dec 31, 2005	-	38 (As on Dec 31, 2021)	-

Design Therapeutics got listed on Mar 26, 2021.

Click here to take a look at Design Therapeutics's IPO in detail

Design Therapeutics has raised a total funding of $171M over 5 rounds. Its first funding round was on Jan 07, 2019. Its latest funding round was a Series B round on Jan 27, 2021 for $*****. 8 investors participated in its latest round. Design Therapeutics has 13 institutional investors.

Here is the list of recent funding rounds of Design Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 27, 2021	5573034	Series B	6604868	5565984	9494719	6655450
Jun 02, 2020	8446748	Series A	3284622	7927990	1362763	4081227
Jul 01, 2019	1368272	Grant (prize money)	9642432	2696296	9644096	National Science Foundation

Access funding benchmarks and valuations. Sign up today!

View details of Design Therapeutics's funding rounds and investors

The founders of Design Therapeutics is Aseem Ansari.

Here are the details of Design Therapeutics' key team members:

Aseem Ansari: Co-Founder of Design Therapeutics.

View details of Design Therapeutics's Founder profiles and Board Members

Design Therapeutics' employee count trend

Design Therapeutics has 67 employees as of Jul 26. Here is Design Therapeutics's employee count trend over the years:

Employee count trend for Design Therapeutics

Uncover Design Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Design Therapeutics include BridgeBio, Alnylam and Alexion. Here is the list of Top 10 competitors of Design Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 8 others	70/100
10th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	Fidelity Investments, T. Rowe Price & 9 others	69/100
35th	Design Therapeutics 2006, Carlsbad (United States), Public	Develops disease-modifying therapies for degenerative disorders	$171M	HTIF, Janus Henderson Investors & 11 others	59/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Design Therapeutics's competitors? Click here to see the top ones

Design Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Design Therapeutics's geography:

Free

US Tech Semi Annual Funding Report

Edition: H1, 2026 (47 Pages)

View all reports related to Design Therapeutics

Media has covered Design Therapeutics for a total of 6 events in the last 1 year, 5 of them have been about company updates and 1 about people movement.